Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 – Systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 – Systematic review and meta-analysis

Published:2021-08 Issue: Volume:158 Page:97-106
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Tomasik Bartłomiej^ORCID,Bieńkowski Michał^ORCID,Braun Marcin^ORCID,Popat Sanjay,Dziadziuszko Rafał^ORCID

Funder

Narodowa Agencja Wymiany Akademickiej

Fundacja na rzecz Nauki Polskiej

Uniwersytet Medyczny w Lodzi

Gdański Uniwersytet Medyczny

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference104 articles.

1. Immune checkpoint inhibitors in the management of lung cancer;Zimmermann;Am. Soc. Clin. Oncol. Educ. Book,2018

2. Real world data in the era of Immune Checkpoint Inhibitors (ICIs): increasing evidence and future applications in lung cancer;Pasello;Cancer Treat. Rev.,2020

3. Simple prognostic model for patients with advanced cancer based on performance status;Jang;J. Oncol. Pract.,2014

4. Treatment of non-small cell lung cancer patients with performance status2 (PS2);Boukovinas;Lung Cancer.,2009

5. Prevalence of poor performance status in lung cancer patients: implications for research;Lilenbaum;J. Thorac. Oncol.,2008

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prevalence and prognostic value of systemic inflammation in good performance status patients with advanced, inoperable non‐small cell lung cancer receiving palliative radiotherapy: Comparison of composite ratios and cumulative scores;Cancer Medicine;2024-08

2. Inclusion, characteristics, and reporting of older adults in FDA registration studies of immunotherapy, 2018–2022;Journal for ImmunoTherapy of Cancer;2024-08

3. Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials;Cancers;2024-06-14

4. Immunotherapy use in older adults with cancer with frailty: A young SIOG review paper;Journal of Geriatric Oncology;2024-05

5. Impact of concurrent medications on the outcome of immunotherapy in non‐small cell lung carcinoma;Thoracic Cancer;2024-04-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3